- Chlamydia and Gonorrhea
- Trichomoniasis and Mycobacterium Genitalis
- Syphilis
- Vulvovaginal Candidiasis
- Bacterial Vaginosis
- Group B Streptococcus
- Herpes Simplex Virus
Middle East STI Diagnostics Market was valued at USD 28.9 million in 2023 and grew at 1.8 % CAGR over the historical years (2019 - 2023). The Middle East - STD Diagnostics Market is projected to reach USD 31.3 million by 2030 at a CAGR of 1.9%. The market is driven by several key factors rising prevalence of STDs, increasing awareness, increasing government initiatives, improved healthcare infrastructure, and technological advancements. Government funding, public-private partnerships, increased focus on home testing kits, and the development of point-of-care (POC) tests are opportunities in the Middle East STD diagnostics market. Focus on multiplex testing, automation of diagnostics, and integration with electronic health records (EHRs) are the trends in the Middle East STD diagnostics market. In the Middle East, only symptomatic patients are getting diagnosed and treated, whereas asymptomatic patients are not receiving treatment and diagnosis. Implementing universal screening for STDs will help in identifying asymptomatic patients and further curb infections in the region.
In terms of volume, a total of 2,345.2 culture tests are done across the Middle East and culture tests dominate the Middle East STD diagnostics market. In the Middle East region, approximately 90% of the rest are done in public labs and 10% are done in private labs. Turkey dominated the Middle East STD testing market and recorded 955.5 thousand culture tests and approximately 638.7 million PCR tests for STI infections in 2023. followed by Saudi Arabia with 365.5 million culture tests and 239.5 million PCR tests. The Middle East STD diagnostics market is expected to grow at a significant CAGR in the coming years. This growth will be driven by factors such as rising awareness of STDs, increasing prevalence of STDs, technological advancements, and government initiatives. However, some constraints need to be addressed, such as the stigma associated with STDs and limited access to healthcare. Overall, the future of the Middle East STD diagnostics market is promising, with opportunities for growth in the development of low-cost diagnostics, increased focus on home testing, and expansion of point-of-care testing.
Middle East STI Diagnostics Market Recent Developments:
- In January 2022, Qiagen announced collaborations with Atila Biosystems and Actome GmbH to expand the applications of its digital PCR platform, QIAcuity.
- In April 2021 - Hologic, Inc. signed a definitive agreement to acquire Mobidiag Oy, a privately held Finnish-French developer of innovative molecular diagnostic tests and instrumentation. The acquisition is valued at approximately $795 million.
Middle East STD Diagnostics Market Dynamics
The prevalence of STIs is on the rise in the Middle East, driven by factors such as unsafe sexual practices, increasing urbanization, and population growth. This is creating a need for more efficient and accessible diagnostic tools, and there is a growing awareness of the importance of sexual health in the Middle East, and people are more likely to get tested for STDs. This is due to factors such as government initiatives, educational campaigns, and the work of NGOs. Governments in Middle East countries are increasingly recognizing the importance of STD prevention and control. They are launching awareness campaigns, promoting safe sex practices, and investing in improving access to STD testing and treatment services. This is creating a favorable environment for the growth of the STD diagnostics market. The healthcare infrastructure in the Middle East is gradually improving, with more clinics and hospitals being built and more healthcare workers being trained. This is making it easier for people to access STD testing and diagnostics. New technologies are emerging that are making STD testing faster, easier, and more affordable. This includes point-of-care tests that can be used in clinics or even at home. Despite the improvements in healthcare infrastructure, there are still many parts of the Middle East where access to STD testing and diagnostics is limited. This is due to a lack of clinics, hospitals, and healthcare workers.
Middle East STD Diagnostics Market Segmentation
By Disease Type
By Diagnostic Test Type
- Cultural Test
- PCR Test
By End User
- Public
- Private
By Country
- Saudi Arabia
- Israel
- Turkey
- Rest of the Middle East
Frequently Asked Questions
The Middle East STI Diagnostics Market was valued at USD 28.9 million in 2023 and grew at 1.8 % CAGR over the historical years (2019 - 2023). The market is projected to reach USD 31.3 million by 2030 at a CAGR of 1.9%.
• Rising Prevalence of STDs
• Increasing Awareness
• Increasing Government Initiatives
• Improved Healthcare Infrastructure
• Technological Advancements.
• Government Funding
• Public-Private Partnerships
• Increased Focus on Home Testing Kits
• The Development of Point-Of-Care (POC) Tests
• Focus on multiplex testing
• Automation of diagnostics
• Integration with electronic health records (EHRs)
Turkey is the dominant region in the Middle East STD Diagnostics Market
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
- Abbott Laboratories
- Bio-Rad Laboratories Inc.
- Danaher Corporation
- Becton, Dickinson and Company
- Qiagen
- Roche Diagnostics
- Hologic, Inc.
- Bio-Rad Laboratories, Inc.
- Cepheid